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Salvianolic acid B (Sal B) is isolated from the traditional Chinese medical herb Salvia
miltiorrhiza and is reported to have a wide range of therapeutic benefits. The aim of this
study was to investigate the effects of Sal B on epithelial barrier dysfunction in rat colitis
and to uncover related mechanisms. Rat colitis model was established by intracolonic
administration of 2, 4, 6-trinitrobenzene sulfonic acid (TNBS). The intestinal barrier
function was evaluated by measuring the serum recovery of fluorescein isothiocyanate-4
kD dextran in vivo and transepithelial electrical resistance in vitro respectively. The protein
expression related to intestinal barrier function was studied using western blotting. The
effects of Sal B on inflammatory responses, oxidative damage and colitis recurrence were
also studied in this study. The intestinal barrier dysfunction in colitis was reversed by Sal B,
accompanied with the decrease of tight junction proteins, and the effect could be blocked
by microRNA-1(miR-1) inhibition. The inflammatory responses, oxidative damage and
colitis recurrence were also decreased by Sal B. The colitis symptoms and recurrences
were ameliorated by Sal B, and restoration of impaired barrier function via downregulation
of MLCK by miR-1 maybe involved in this effect. This study provides some novel insights
into both of the pathological mechanisms and treatment alternatives of inflammatory
bowel disease.
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INTRODUCTION
Inflammatory bowel disease (IBD) is complex multi-factorial inflammatory diseases, of which
Crohn’s disease (CD) and ulcerative colitis (UC) are the two most common forms (Garcia de Tena
et al., 2002). IBD are important diseases of the gastrointestinal tract and are associated with a high
degree of patient impairment and treatment cost.
The pathogenesis of IBD is not fully understood at present, but it has been reported that the
development of IBD is thought to be related to a combination of genetic and environmental
factors (Matricon et al., 2010). Role of free radicals and epithelial barrier functions has attracted
much attention in the pathogenesis of IBD recently (Almenier et al., 2012). As is known that
abnormal mucosal immune reactions to lumenal content is a course of tissue damage in IBD
(Simmonds et al., 1992). Infiltration of inflammatory cells into the mucosa and release of free
radicals, such as reactive oxygen species (ROS) and reactive nitrogen species, could lead to
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inflammatory cascade (Almenier et al., 2012; Nagib et al., 2013).
Tissue damage and additional recruitment of inflammatory cells
could be caused by these free radicals, which then sustain the
inflammatory cascade (Keshavarzian et al., 2003; Reuter et al.,
2010; Almenier et al., 2012).
IBD could be evoked or aggravated by defective intestinal
barrier function and the characteristics of epithelial tight junction
defines intestinal barrier function with intact epithelium (Su
et al., 2009, 2013; Al-Sadi et al., 2013) Restoration of barrier
function maybe a promising way to alleviate IBD (Clayburgh
et al., 2004). The high expression of myosin light chain
kinase (MLCK), which induces contraction of the perijunctional
actomyosin ring through myosin light chain phosphorylation,
plays an important role in the increase of intestinal permeability
and epithelial barrier dysfunction (Cunningham and Turner,
2012; Al-Sadi et al., 2013). MLCK regulation in epithelial barrier
dysfunction may provide future therapeutic targets to treat
intestinal diseases.
Micro RNAs (miRNAs) is a series of small non-coding
RNA molecules (containing 20–25 nucleotides) found in
eukaryotes, functioning in RNA silencing, post-transcriptional,
and translation regulation of gene expression (Ambros, 2004;
Bartel, 2004). Aberrant expression of miRNAs is involved
in the pathophysiology of human diseases and it have been
proved to be novel therapeutic targets for inflammation, cancer,
and cardiovascular diseases (Chen, 2007; Bogatcheva et al.,
2011). MicroRNA-1(miR-1) was shown to protect endothelial
permeability through inhibition of myosin light chain kinase in
cardiovascular disease (Hua et al., 2013). Previous studies showed
that more and more polyphenols possess beneficial effects
on human health through targeting of miRNA (Milenkovic
et al., 2013; Tomé-Carneiro et al., 2013). Therefore, miR-1 may
alleviate IBD symptoms through restoring the impaired barrier
function. Our previous results showed that Sal B treatment
affected the expression of miR-1 in vitro. In the present study,
we determine whether Sal B could restore the impaired barrier
function in rat colitis model through modulation of miR-1.
Salvia miltiorrhiza, also known as Danshen, has been widely
used for thousands of years in traditional Chinese medicine,
with little reported toxicity (Kim et al., 2005). As one of the
major water soluble components of Radix Salvia miltiorrhiza,
salvianolic acid B (Sal B) was shown to exert antioxidant activity
(Li et al., 2015) and our pre-experiments also showed that Sal
B restored abnormal intestinal permeability in Caco-2 cells.
Sal B has been reported to possess a wide range of biological
activities including anti-inflammatory, anti-oxidant, and anti-
carcinogenic effects (Yao et al., 2009; Li et al., 2014). Colitis
model was established by intracolonic administration of 2,4,6-
trinitrobenzene sulfonic acid (TNBS), which is classic model for
studying barrier function in IBD (Turner, 2009; Morampudi
et al., 2014). Severe colonic damage, which is associated with
high myeloperoxidase (MPO) activity and is mainly known as
a reflection of neutrophilic infiltration into the damaged tissue,
could be induced by TNBS dissolved in ethanol (Veljaca et al.,
1995). The effects of Sal B on colitis were evaluated from the
decrease of epithelial permeability and free radical scavenging,
respectively. The effects of Sal B on the recurrence of colitis
induced by interleukin-1 beta (IL-1β) were also investigated
based on its protective effects on epithelial barrier function.
MATERIALS AND METHODS
Animals
Sprague-Dawley male rats (5–7 weeks of age, weighing 140–160
g) were purchased from the Experimental Animal Center, Dalian
Medical University [Certificate of Conformity: No. SYXK (Liao)
2013–0006]. This study was carried out in accordance with “the
recommendations of the National Institutes of Health Guide for
Care and Use of Laboratory Animals (Publication no. 85–23,
revised 1985) and Dalian Medical University Animal Care and
Ethics Committee.” The experimental protocol was approved by
“Dalian Medical University Animal Care and Ethics Committee”
at Dec. 8th, 2015. The animal protocol was designed to minimize
pain or discomfort to the animals. The animals were acclimatized
to laboratory conditions (23◦C, 12/12 h light/dark, 50%
humidity, ad libitum access to food and water) for 2 weeks prior
to experimentation and no animals died before experiments.
Reagents
Sal B (Purify speciation: ≥98%) was obtained from the Chinese
National Institute for the Control of Pharmaceutical and
Biological Products (Beijing, China). Sulfasalazine (SASP) was
purchased from Tianjin Kingyork Group Co. Ltd. (Tianjin,
China). The NADPH oxidase 4 (NOX4) antibodies, superoxide
dismutase 2 (SOD2) antibodies, malondialdehyde 5 (MDA 5)
antibodies, glutathione 2 (GSH 2) antibodies, MLCK antibodies,
ZO-1 antibodies, and occludin antibodies were obtained from
Abcam (Hong Kong) Ltd. (Hong Kong, China); iNOS antibodies
were obtained from Beijing Biosynthesis Biotechnology Co. Ltd
(Beijing, China). Claudin-2 antibodies were obtained from Life
Technologies (Carlsbad, CA, USA). Other agents were purchased
from Sigma-Aldrich (Saint Louis, MO, USA).
Experimental Design
One hundred rats were randomly divided into five groups, each
consisting of 20 rats. Group I served as sham operation group
with intracolonic administration of equal volume of ethanol, then
receive the gavage treatment of PBS. Groups II, III, IV, V were
subjected for the induction of colitis. Group II served as the
TNBS colitis group (TNBS) and groups III, IV, and V received
treatment of SASP (TNBS+SASP, 100 mg/kg b.wt, intragastric,
dissolved in saline), Sal B(L) (TNBS+Sal B(L), 20 mg/kg b.wt,
intragastric, dissolved in saline), and Sal B(H) (TNBS+Sal B(H),
80 mg/kg b.wt, intragastric, dissolved in saline), respectively. IBD
recurrence in different groups was observed after intraperitoneal
(ip) injection of recombinant IL-1β for 48 h (from day 15 to 16;
Figure 1).
Colitis Induced by TNBS and Recurrence
of Colitis with Intraperitoneal Injection of
IL-1β
The rat colitis model was induced according to the previous
reports with slight modification (Morris et al., 1989; Aube
et al., 1999). Briefly, a catheter was inserted to the level of
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FIGURE 1 | Experimental flowchart for the present study.
FIGURE 2 | Salvianolic acid B (Sal B) induced modulations on oxidative stress and epithelial barrier function in normal rats. After gavage administration of
Sal B once a day for seven consecutive days, the contents of (A) NADPH oxidase 4 (NOX4), (B) inducible nitric oxide synthase (iNOS), (C) malondialdehyde (MDA),
(D) glutathione (GSH), (E) superoxide dismutases (SOD), and (F) long myosin light chain kinase (MLCK) from colon tissue in normal control (NC) rats were observed
using ELISA methods; (G) the effects of Sal B on the serum recovery of FD-4 was also observed. Data are expressed as the mean ± SD. **P < 0.01, compared with
the NC group (n = 6). Data in the NC group is set to 100%; other data are the relative values compared with those in the NC group. Sal B(L), 20 mg/kg Sal B; Sal
B(H), 80 mg/kg Sal B.
the splenic flexure (8 cm proximal to the anal verge) after a
fasting period of 24 h with free access to drinking water, under
urethane anesthesia. TNBS dissolved in ethanol (40%V/V) was
then infused to the colon at a dose of 125 mg/kg. The sham group
rats were similarly treated but infused with 1 mL ethanol. Rats
were allowed to eat and drink ad libitum 1 h later. Biochemical
studies were then performed using full thickness of intestinal wall
in the distal colonic samples. The study of colitis recurrence was
conducted according to the methods reported previously with
modifications (Watanabe et al., 1997; Young Oh et al., 2008).
Briefly, the recurrence of colitis after SASP or Sal B treatment was
induced by giving rats recombinant human IL-1β (150 µg/kg)
intraperitoneally for 48 h from day 15. At day 17, the colitis
symptoms were checked to test weather colitis recurrence was
found.
Assessment of Inflammation
Inflammatory factors of colitis model including animal
body weights, diarrhea incidence, and total food intake
were recorded everyday. Colon macroscopically visible
damage was measured using a 0–10 scale (Orsi et al.,
2014). According to the morphological criteria described
previously, routine hematoxylin and eosin (HE)-stained
colon section was measured to represent the degree of
inflammation (Cooper et al., 1993; Ghia et al., 2008; Schwanke
et al., 2013). After being sacrificed, the colon tissues of
the animals were embedded in paraffin and fixed in 10%
formalin for at least 24 h. The samples were then cut into
5 mm pieces and fixed on slides according to the routine
procedure. Colon sections were HE-stained (or used for other
immunohistochemistry studies). Then, the samples were
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FIGURE 3 | Salvianolic acid B (Sal B) ameliorated colitis symptoms. (A) Hematoxylin and eosin (HE)- staining analysis of rat colonic tissue. Effects of Sal B on
(B) body weight, (C) food intake, (D) macroscopically visible damage, and (E) colon weight-to-length ratio in colitis rats. Data are expressed as the mean ± SD. **P <
0.01 compared with the sham group (n = 7); ##P < 0.01 compared with the TNBS control group (n = 7). SASP, sulfasalazine; Sal B(L), 20 mg/kg Sal B; Sal B(H), 80
mg/kg Sal B.
FIGURE 4 | Salvianolic acid B (Sal B) reduced neutrophil infiltration and cytokine profiles. ELISA results of Sal B-induced effects on proinflammatory cytokine
(A) TNF-α, (B) IL-6, (C) IL-1β, and (D) myeloperoxidase (MPO) from rat colon tissue. Data are expressed as the mean ± SD; **P < 0.01 compared with the sham
group; ##P < 0.01 compared with the TNBS control group (n = 7). SASP, sulfasalazine; Sal B(L), 20 mg/kg Sal B; Sal B(H), 80 mg/kg Sal B.
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FIGURE 5 | Salvianolic acid B (Sal B) restored barrier function through decreasing intestinal permeability. (A) Effects of Sal B on the serum recovery of
FD-4. Effects of Sal B on tight junction protein expression of claudin-2 and zona occludens ZO-1 from colon tissue using western blotting (B) and
immunofluorescence technique (C). Data are expressed as the mean ± SD; **P < 0.01 compared with the sham group; ##P < 0.01 compared with the TNBS
control group (n = 7). Data in the sham group is set to 100%; other data are the relative values compared with those in the sham group. SASP, sulfasalazine; Sal B(L),
20 mg/kg Sal B; Sal B(H), 80 mg/kg Sal B.
analyzed by light microscopy (Nikon Eclipse TE2000-U, Nikon
Corp., Tokyo, Japan).
Evaluation of Epithelial Barrier Function
According to the previous literatures, intestinal permeability
(barrier function) was measured in vivo as follows. Rats were
fasted but free to water for 3 h. Then, rats received gavage
treatment of 80 mg/mL fluorescein isothiocyanate-4 kD dextran
(FD-4) (Sigma, St. Louis, MO, USA). After 1 and 3 h later,
serum was harvested and measured using a Synergy HT plate
reader (BioTek, Winooski, VT, USA), respectively. Intestinal
permeability was represented with enhanced serum recovery of
FD-4.
Intestinal barrier function in vitro was studied by
measurement of transepithelial electrical resistance (TER).
Induced TER is parameter of disturbed intestinal barrier
function (Smith and Clark, 2010; O’Malley et al., 2012). TER of
filter-grown Caco-2 intestinal monolayers was measured using
an epithelial voltohmmeter. Caco-2 cells (4 × 105) were seeded
in the upper chamber of a transwell filter. TER of Caco-2-plated
filters was measured daily. After TER reached to a steady state
(always 540± 12/cm2) 5 days later, Caco-2-plated filters could
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FIGURE 6 | Salvianolic acid B (Sal B) reversed the altered
microRNA-1(miR-1) and MLCK expression. Effects of Sal B on the
expression of (A) miR-1 and (B) MLCK in rat colitis model was measured.
Data are expressed as the mean ± SD; **P < 0.01 compared with the sham
group; ##P < 0.01 compared with the TNBS control group (n = 7). Data in
the sham group is set to 100%; other data are the relative values compared
with those in the sham group. SASP, sulfasalazine; Sal B(L), 20 mg/kg Sal B;
Sal B(H), 80 mg/kg Sal B.
be used to establish barrier function model. Barrier dysfunction
cellular model was established in Caco-2 monolayers exposed
with IL-1β (10 ng/mL). TER always decreased to 340± 9/cm2
after IL-β treatment (Al-Sadi and Ma, 2007). Sal B (20, 40, 80
µM) could reverse the decreased TER level to (350 ± 10.5–450
± 9 /cm2). The relative TER in Sal B treatment group was
calculated as a percentage of IL-1β control group and TER in
IL-1β control group was set to 100%. TER determination was
repeated for at least three times.
Quantitative RT-PCR
As previously described, total RNA was isolated with RNeasy
mini kit (Qiagen) (Chang-Qing et al., 2009). RNA samples
with an A260/280 ratio between 1.9 and 2.1 were used. A
TaqMan miRNA Reverse Transcription Kit was used for reverse
transcription assay. A TaqMan miRNA assay Kit (GenePharma
Corp.) and Applied Biosystems 7500 FAST System (Applied
Biosystems, Foster City, CA, USA) were used for mature miRNA
measurement. U6 was used as an internal control. The levels of
miRNA were determined using the formula 2−11Ct.
Dual Luciferase Reporter Assays
Plasmid DNA (wt-Luc-MLCK, mut-Luc-MLCK, or control
vector) and antago-miR-1 or the antago-miR negative control
were co-transfected into Caco-2 cells. Cells were incubated
with 20, 40, and 80 µM Sal B 24 h after transfection,
respectively. After 24 h, reporter assays were performed.
Dual-Light Chemiluminescent Reporter Gene Assay System
(Berthold, Germany) was used to measure luciferase
activity, which then was normalized to Renilla luciferase
activity.
Measurement of ROS Production
The ROS content in RAW264.7 cells was measured using flow
cytometry according to previous reports (Abdul-Sater et al.,
2010). Briefly, RAW264.7 cells were plated in phenol red-
free DMEM containing 10% FBS and then infected and/or
treated for the indicated times. Cells were detached using
TrypLETM Express, loaded with 2.5 µM DCF in PBS for
15 min at 37◦C, washed with PBS, resuspended in growth
medium, and finally analyzed by flow cytometry with a Guava
EasyCyte system with a 15-mW argon ion laser at 488 nm.
Fluorescence was measured on the FL1 (green) channel, gating
only on live cells. RAW264.7 cells were treated with IL-1β
or Sal B. Non-treated RAW264.7 cells served as normal
control.
Western Blot Analysis
Total Protein Extraction Kit (KeyGEN Bio TECH, Nanjing,
China) was used for total protein isolation from full thickness
of intestinal wall. BCA Protein Assay Kit (Beyotime Institute
of Biotechnology, Haimen, China) was used for protein
concentration determination. The blots on PVDF membrane
were respectively probed with corresponding protein antibodies
including MLCK antibody [1:1000; Abcam (Hong Kong) Ltd.],
claudin-2 antibody (1:800; Santa Cruz Biotechnology Co. Ltd.,
Shanghai, China), iNOS antibody [1:1000; Abcam (Hong Kong)
Ltd.], COX-2 antibody [1:1000; Abcam (Hong Kong) Ltd.], and
NF-KappaB-p65 antibody [1:1000; Abcam (Hong Kong) Ltd.],
respectively. Multi Spectral imaging system (UVP, Cambridge,
UK) was used to detect and quantify the bands for special protein
determination.
Statistical Analysis
In this study, data from rats in sham group was studied compared
with that in TNBS group using One-Way ANOVA firstly, and
then the data from rats in saline+TNBS, Sal B+TNBS, and
SASP+TNBS group was studied compared with that in TNBS
group using pair wise comparison of each group to each group in
One-Way ANOVA. Data were expressed as the mean ± S.D. All
experiments were repeated for at least three times or in multiple
animals as indicated. ∗∗p < 0.05 was considered as significantly
different.
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FIGURE 7 | MicroRNA-1(miR-1) mediated Sal B-induced restoration effects by targeting of MLCK. (A) Sal B abrogates the increase in MLCK following
miR-1 repressed. (B–C) Sal B abrogates the increase in MLCK following miR-1 repressed. The data are presented as the mean ± SD. (n = 3). **P < 0.01 vs. the
antago-miR control group, ##P < 0.01 vs. miR-1 or MLCK before Sal B treatment respectively.
RESULTS
Salvianolic Acid B-Induced Modulations on
Oxidative Stress and Epithelial Barrier
Function in Normal Rats
The cytotoxicity of Sal B was studied in mouse macrophage
cell line RAW264.7. Sal B in the dose range of 5–1280 µM
showed almost no cytotoxicity effects (data not shown). Based on
these pre-experiments and preliminary results reported by other
researchers, 20 mg/kg (low dose) and 80 mg/kg (high dose) Sal B
were selected for animal experiments.
The effects of Sal B on oxidative stress and epithelial barrier
function in normal rats were respectively studied before the
analysis of Sal B induced modulation on those in colitis rats.
ELISA results showed that the low dose and high dose of Sal
B did not affect the expression of NOX4, iNOS, MDA, GSH,
and SOD (Figures 2A–E) from colon tissue, while the high dose
of Sal B decreased the expression of long MLCK (Figure 2F)
from colon tissue. The serum recovery of FD-4 in normal rats
was not changed after Sal B treatment, which indicates that Sal
B does not affect the intestinal barrier function of normal rats
(Figure 2G).
General Conditions Observed in Rats
Rats in the phosphate buffered saline (PBS) group (intracolonic
administration of PBS) woke up about 1 h after anesthesia
with no abnormal inflammatory symptoms found, compared
to normal control rats with no operation. Rats in the ethanol
group (intracolonic administration of ethanol) woke up about 1
h after anesthesia and symptoms presented within the first 2 days,
including shapeless stool and loss of appetite. The symptoms
disappeared after 3 days of ethanol treatment. Three days after
the operation, HE-staining results of colonic tissue showed no
difference between ethanol/PBS treated rats and normal control
rats (data not shown). In the following study, the ethanol group
was set as the sham group to study the effects of Sal B induced
modulation in colitis rats.
The rats in the TNBS group woke up about 2 h after
anesthesia with symptoms including shapeless stool, increased
stool frequency, outflow of red or dark red liquid from the anus,
positive fecal occult blood test, and loss of appetite; the symptoms
peaked on the 3rd day and lasted for about 7 days. After 7 days of
TNBS induction, the shapeless stools were also seen in the TNBS,
Sal B, and SASP treated groups but fecal occult blood test was
negative. No rats, three rats, two rats, two rats, and two rats died
in the ethanol, TNBS, SASP, low, and high dose Sal B groups,
respectively.
Salvianolic Acid B Treatment Ameliorated
Colitis Symptoms
Significant lower body weight and food intake were observed
in the sham group after the induction of inflammation
(Figures 3B,C). Successful establishment of colitis was
confirmed with biochemical and macroscopic analysis. Increased
macroscopically visible damage and colon weight-to-length ratio
were observed after TNBS treatment (Figures 3D,E). Sal B (20
and 80 mg/kg) and SASP significantly ameliorated the colitis
symptoms induced by TNBS, which included an increase in
body weight and food intake, and a decrease in macroscopically
visible damage and colon weight-to-length ratio (Figures 3A–E).
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FIGURE 8 | Sal B-induced restoration effects was abolished by
microRNA-1(miR-1) inhibition in vitro. (A) Sal B-induced inhibition on tight
junction proteins claudin-2 and zona occludens (ZO-1) contents and (B)
stimulation on transepithelial electrical resistance (TER) levels were abolished in
the present of miR-1 inhibition. The data are presented as the mean ± SD.
(n = 3). ##P < 0.01 vs. tight junction proteins or TER levels before Sal B
treatment respectively.
Together, these data show that Sal B can suppress inflammation
in the TNBS-induced colitis model.
Salvianolic Acid B Reduced Neutrophil
Infiltration and Cytokine Profiles
Initiation of colonic inflammation often associates with the
enhancement of neutrophil infiltration and levels of pro-
inflammatory cytokines (Scull et al., 2010; Bian et al., 2012; Lin
et al., 2016). Neutrophil infiltration into the damaged tissue
is represented by MPO activity (Piegeler et al., 2014). Pro-
inflammatory cytokines (TNF-α, IL-1β, and IL-6) levels and
MPO activity from colitis rat colon tissue were significantly
increased compared to those in sham group (Figures 4A–D).
Increased MPO activity and changes in cytokine levels were
reversed by SASP and Sal B (20 or 80 mg/kg) treatment.
Salvianolic Acid B Restored Impaired
Barrier Function in vivo
A significant increase in serum recovery of FD-4 in the TNBS
control group compared with the sham group was found after
14 days of the inflammation induction (Figure 5A), which
was accompanied with the increase of tight junction protein
expressions like claudin-2 and zona occludens (ZO-1) in the
TNBS control group (Figure 5B). Immunofluorescence results of
claudin-2 and ZO-1 was also enhanced in TNBS control group,
compared with in normal control (Figure 5C). These results
indicate that the intestinal barrier dysfunction was not restored,
although HE-staining results showed that the epithelium was
almost intact in the TNBS control group. After 13 days of
Sal B treatment, all these changes were reversed. The high
expressions were significantly decreased by Sal B but not
SASP.
MiR-1 Activation and MLCK Inactivation
was Involved in Sal B-Induced Restoration
of Barrier Function
To test our hypothesis that Sal B-induced restoration of barrier
function is mediated by miR-1/MLCK pathway, we measured
the effects of Sal B on miR-1 and MLCK expressions in
colitis rat model. As shown in Figure 6, miR-1 expression was
decreased in TNBS model group, while MLCK protein content
was significantly increased. Sal B treatment reversed the changes
of expression of miR-1 and MLCK respectively, however, SASP
did not alter miR-1 and MLCK expression in rat colitis model
(Figure 6).
MiR-1 Mediated Sal B-Induced Restoration
Effects by Targeting of MLCK
Antago-miR-1 and luciferase reporter plasmids containing
the miR-1-MLCK response element (wt-Luc-MLCK) or a
mutant miR-1-MLCK response element (mut-Luc-MLCK)
were co-transfected to Caco-2 cells in the presence or
absence of Sal B, respectively. Luciferase activity was
significantly decreased by Sal B treatment and this effect
was significantly blocked by miR-1 inhibitor. However, these
effects were not observed with the mutated MLCK-3′-UTR
(Figure 7A).
To further elucidate the cellular effects of Sal B on MLCK,
Caco-2 cells with antago-miR-1 were transfected in the presence
or absence of Sal B, respectively. And the expression levels of
miR-1 and MLCK were also determined. MiR-1 expression in
Caco-2 cells was significantly increased by Sal B incubation
and this effect could be blocked by cell transfection with
miR-1 inhibitor (Figure 7B). The high expression of MLCK in
Caco-2 cells induced by IL-1β was significantly decreased by
Sal B treatment, however, after cell transfection with miR-1
inhibitor, the inhibitory effect of Sal B on MLCK expression
was significantly blocked (Figure 7C). Sal B decreased the
enhanced protein levels of claudin-2 and ZO-1 triggered by
IL-1β. Sal B also reversed the reduced TER levels induced by
IL-1β (Figure 8). These effects of Sal B on claudin-2, ZO-1
expression and TER changes were also significantly blocked
by miR-1 inhibition. Thus, we concluded that Sal B targeted
miR-1, induced downregulation of MLCK and finally resulted
in restoration of defective tight junction barrier function in rat
colitis model.
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FIGURE 9 | Salvianolic acid B (Sal B) increased the antioxidant capacity. Effects of Sal B on protein expression of (A) NADPH oxidase 4 (NOX4), (B) inducible
nitric oxide synthase (iNOS), (C) malondialdehyde (MDA), (D) glutathione (GSH), (E) superoxide dismutases (SOD) in colon tissue; (F) Effects of Sal B on reactive
oxygen species (ROS) production in RAW264.7 cells. Data are expressed as the mean ± SD; **P < 0.01 compared with the sham (colon tissue) or normal (cell) group;
##P < 0.01 compared with the TNBS (IL-1β) control group (n = 7). Data in the normal or sham group is set to 100%; other data are the relative values compared
with those in the sham group. SASP, sulfasalazine; Sal B (L), 20 mg/kg Sal B; Sal B (H), 80 mg/kg Sal B.
Salvianolic Acid B Increased the
Antioxidant Capacity in Vivo and in Vitro
Protein expressions of NOX4, iNOS, andMDAwere significantly
increased, while GSH and SOD were significantly decreased
compared to those in the sham group after the induction
of inflammation (Figures 9A–E). ROS levels determined
using flow cytometry was increased after IL-1β treatment
in vitro (Figure 9F). These data show that the antioxidant
system in colitis model may be destroyed. Sal B treatment
increased the antioxidant capacity, which decreased the
protein expressions of NOX4, iNOS, MDA, and ROS levels,
and increased the protein expression of GSH and SOD
(Figures 9A–F).
Analysis of Colitis Recurrence Induced by
IL-1β After Sal B Treatment
After 13 days of treatment by SASP or Sal B, the symptoms in
colitis rats were significantly alleviated, this can be proved by
morphological or histological checks (Figure 3). However, the
defective tight junction barrier function in the TNBS group was
not significantly affected by SASP (Figure 5). Recurrence analysis
was carried out in order to study the potential of Sal B for
treatment of colitis. As shown in Figure 10, ip administration
of IL-1β at day 15 after TNBS induced colitis led to 90% of
colitis recurrence in the SASP treated group, 10% in the Sal
B(L) treated group, and 20% in the Sal B(H) treated group.
Significantly attenuated levels of inflammatory cytokines TNF-α,
MPO, macroscopically visible damage score, and colon weight-
to-length ratio were responsible for the resistance to colitis
recurrence in Sal B treated group (Figure 10).
DISCUSSION
In the present study, the effects of Sal B on colitis were assessed
morphologically, histologically and pharmacologically in a
TNBS-induced rat colitis model. Sal B significantly ameliorated
the symptoms induced by TNBS, including decreasing the gross
damage score, MPO activity, and cytokine profiles compared
with those in the TNBS control group. The enhanced intestinal
epithelial permeability in the TNBS control group was decreased
by Sal B. Both SASP and Sal B alleviated TNBS induced colitis.
Sal B restored the defective tight junction barrier function.
However, SASP, as a well-known anti-inflammation drug, exerted
no effects on disturbed tight junction barrier function. The
defective tight junction barrier function leads to increased
intestinal permeability and finally aggravates IBD (Su et al.,
2013). Our results also showed that Sal B-induced restoration
of defective tight junction barrier function has a protective
effect against IL-1β-induced colitis recurrence. Therefore, Sal B
induced restoration of impaired tight barrier function play an
important role in the treatment of colitis as well as the colitis
recurrence.
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FIGURE 10 | Analysis of colitis recurrence induced by IL-1β (10 ng/mL). (A) HE-staining analysis of colitis recurrence induced by IL-1β (10 ng/mL) after SASP or
Sal B treatment in rat colonic tissue. Effects of Sal B on (B) macroscopically visible damage, (C) colon weight-to-length ratio, (D) myeloperoxidase (MPO), (E)
proinflammatory cytokine TNF-α. Data are expressed as the mean ± SD; **P < 0.01 compared with as indicated (n = 10). Data in the sham group is set to 100%;
other data are relative values. SASP, sulfasalazine; Sal B(L), 20 mg/kg Sal B; Sal B(H), 80 mg/kg Sal B.
MicroRNAs play an important role in a wide range of
pathophysiological cellular processes (Chen, 2007; Bogatcheva
et al., 2011). Aberrant expression of miRNAs, which have been
proved to be novel therapeutic targets for human diseases,
is involved in the pathophysiology of a number of human
diseases including inflammation, cancer, cardiovascular diseases
(Milenkovic et al., 2013; Tomé-Carneiro et al., 2013). In
this study, we found that Sal B targeted miR-1, induced
downregulation of MLCK and finally resulted in restoration
of defective tight junction barrier function in rat colitis
model. Therefore, miR-1 may alleviate colitis symptoms through
restoring the impaired barrier function. Epithelial permeability in
the TNBS control group was significantly increased compared to
the sham group; and the increase could be significantly decreased
by Sal B treatment, which was accompanied with a decrease
in the expression of tight junction proteins including claudin-2
and ZO-1 (Poritz et al., 2007; Bai et al., 2008; O’Driscoll et al.,
2010). After 14 days of the inflammation induction operation,
HE-staining results showed that the epitheliumwas almost intact,
a significantly increased serum recovery of FD-4 in the TNBS
control group was also found. The tight junction proteins levels
were also significantly increased in the TNBS control group
compared to those in the ethanol group, which proves that
intestinal barrier function with intact epithelium is factually
defined by epithelial permeability.
The colitis model induced by TNBS (diluted in 50%
ethanol) is useful in following temporal changes of inflammation
visually and histologically, and is appropriate for the study
of inflammatory responses, as well as epithelial alterations
upon mucosal damage (González et al., 2009; Lejeune et al.,
2010; Brenna et al., 2013). In the SASP treated group, the
inflammatory responses were significantly decreased compared
with those in the TNBS control group; however, the high
epithelial permeability was almost unchanged. After intestinal
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resection there is a high symptomatic recurrence rate in the
first year after surgery (Lochs et al., 2000; Rutgeerts, 2002).
Anti-inflammation therapy (SASP, other 5-aminosalicylic acid
formulations or probiotics) has limited value in the prophylaxis
of colitis recurrence (Lochs et al., 2000; Prantera et al., 2002).
We proposed that Sal B induced restoration of epithelial barrier
function may supply some new treatment alternatives for the
prophylaxis of colitis recurrence.
In the case of radical scavenging activity, results in the present
study showed that the content of cellular ROS, colonic nitric
oxide (NO) and the cytokine profiles including TNF-α, IL-6,
and IL-1β was significantly decreased by gavage administration
of Sal B. The infiltration of inflammatory cells is regarded as a
trigger of free radical release (Bhaskar et al., 1995), which then
attack cellular structure through the inhibition of endogenous
defense systems (Pham-Huy et al., 2008; Wu et al., 2013).
In this study, TNBS-induced oxidative stress was indicated
by the elevation of NOX4, inducible nitric oxide synthase
(iNOS), MDA level, and overwhelming GSH and SOD levels,
finally led to the increased accumulation of ROS and NO. The
serious imbalance between the production of free radicals and
antioxidant defense in colitis could be significantly reversed by
Sal B. HE-staining results showed that the alterations in the TNBS
control group, including epithelial necrosis, impaired mucosa
involving submucosa with hyperemia and edema, and ulceration
accompanied with numerous inflammatory cell infiltrations,
were alleviated by gavage administration of Sal B.
In conclusion, Sal B could restore barrier function, which was
mediated by the activation of miR-1 and the subsequent MLCK
inactivation. The restoration effect of epithelial barrier function is
also beneficial for the prophylaxis of colitis recurrence. Inhibition
of oxidative stress and reduction of cytokine secretion is involved
in Sal B exerted anti-inflammatory effect. Such data may provide
some novel insights that might help to develop more treatment
alternatives for IBD.
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